<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662019000400525</article-id>
<article-id pub-id-type="doi">10.24245/mim.v35i4.2486</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento farmacológico de la diabetes mellitus tipo 2 dirigido a pacientes con sobrepeso y obesidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacological treatment of diabetes mellitus type 2 directed to patients with overweight and obesity]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mellado-Orellana]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salinas-Lezama]]></surname>
<given-names><![CDATA[Erika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Herrera]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guajardo-Lozano]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Weber]]></surname>
<given-names><![CDATA[Federico Leopoldo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>4</numero>
<fpage>525</fpage>
<lpage>536</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662019000400525&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662019000400525&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662019000400525&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La diabetes mellitus tipo 2 es una enfermedad multifactorial y de carácter crónico que requiere un tratamiento integral a lo largo de la vida del paciente y con necesidad de ajustes constantes de acuerdo con los requerimientos específicos de cada paciente. Se ha identificado que la disminución de peso en pacientes diabéticos puede retrasar la progresión de la enfermedad e incluso retrasar o evitar su aparición. Además de ser un factor benéfico en las metas de tratamiento de los pacientes diabéticos, la disminución del peso puede lograr cambios clínicamente significativos en las concentraciones totales de glucosa sérica, hemoglobina glucosilada (HbA1C) y en las concentraciones de triglicéridos. En la actualidad las recomendaciones basadas en evidencia están dirigidas a la intervención farmacológica, quirúrgica y cambios en el estilo de vida en el manejo de la obesidad como parte del tratamiento integral de los pacientes con diabetes mellitus tipo 2. Los tratamientos farmacológicos tradicionales contra la diabetes mellitus tipo 2 pueden aumentar aún más el peso y esto puede disminuir los beneficios del control glucémico adecuado. Es importante identificar la injerencia de cada grupo de fármacos en el peso.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Diabetes mellitus type 2 (DM2) is a chronic and multifactorial disease that requires an integral treatment throughout the life of the patient and in need of constant adjustments according to specific requirements of each patient. It is well established that weight loss in diabetic patients may delay the progression of the disease or even delay its onset. In addition to being a beneficial factor in the treatment goals of diabetic patients, weight reduction can achieve clinically significant changes in serum glucose, glycated hemoglobin (HbA1c) and triglyceride levels. Evidence-based recommendations are currently aimed at pharmacological, surgical and lifestyle changes in the management of obesity as part of the comprehensive treatment of patients with diabetes mellitus type 2. Traditional pharmacological treatments for diabetes mellitus type 2 may further increase weight and this may decrease the benefits of adequate glycemic control. It&#8217;s important to identify the interference of each drug group on weight.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[pérdida de peso]]></kwd>
<kwd lng="es"><![CDATA[hemoglobina glucosilada]]></kwd>
<kwd lng="es"><![CDATA[obesidad]]></kwd>
<kwd lng="en"><![CDATA[Diabetes mellitus type 2]]></kwd>
<kwd lng="en"><![CDATA[Weight loss]]></kwd>
<kwd lng="en"><![CDATA[Glycated hemoglobin]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[Diabetes Care 2017]]></source>
<year></year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Diabetes Care 2017]]></source>
<year></year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>48-56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flegal]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Kit]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Ogden]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of obesity and trends in the distribution of body mass index among US adults 1999-2010]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2012</year>
<volume>307</volume>
<page-range>491-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Centers for Disease Control and Prevention</collab>
<source><![CDATA[National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta,]]></source>
<year>2011</year>
<publisher-loc><![CDATA[GA ]]></publisher-loc>
<publisher-name><![CDATA[Center for Disease Control and Prevention, US Department of Health and Human Services]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermansen]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Mortensen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Drug Safety]]></source>
<year>2007</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1127-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogurtsova]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha Fernandes]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Linnenkamp]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Guariguata]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IDF Diabetes Atlas Global estimates for the prevalence of diabetes for 2015 and 2040]]></article-title>
<source><![CDATA[Diabetes Research and Clinical Practice]]></source>
<year>2017</year>
<volume>03</volume>
<page-range>24</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornell]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[D'Souza]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacotherapy considerations in diabetes and obesity]]></article-title>
<source><![CDATA[Setting patients up for success]]></source>
<year>2016</year>
<volume>126</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inzucchi]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bergenstal]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of hyperglycemia in type 2 diabetes a patient centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>1364-79</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>Instituto Nacional de Salud Pública</collab>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición (ENSANUT) de Medio Camino 2016 Informe Final de Resultados]]></source>
<year>2016</year>
<page-range>31-10</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abrahamson]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barzilay]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AACE Comprehensive diabetes management]]></article-title>
<source><![CDATA[Endocr Prac]]></source>
<year>2013</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>327-36</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saaristo]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Barengo]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Korpi-Hyövälti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oksa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Puolijoki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Saltevo]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population, BMC Public]]></article-title>
<source><![CDATA[Health]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>423</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindström]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ilanne-Parikka]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Peltonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aunola]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eriksson]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Hemiö]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention follow-up of the Finnish Diabetes]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2006</year>
<volume>368</volume>
<numero>9548</numero>
<issue>9548</issue>
<page-range>1673-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegría-Ezquerra]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Castellano-Vázquez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Alegría-Barrero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesidad, Síndrome metabólico y diabetes implicaciones cardiovasculares y actuación terapéutica]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2008</year>
<volume>61</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>752-64</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Berne]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Danchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention Study ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2013</year>
<volume>34</volume>
<numero>39</numero>
<issue>39</issue>
<page-range>3035-87</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<source><![CDATA[Diabetes Care 2017]]></source>
<year></year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S34-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Purnell]]></surname>
<given-names><![CDATA[JQ]]></given-names>
</name>
<name>
<surname><![CDATA[Hokanson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Marcovina]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure results from the DCCT: Diabetes Control and Complications Trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1998</year>
<volume>280</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>140-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Purnell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Weight effect of current and experimental drugs for diabetes mellitus from promotion to alleviation of obesity]]></article-title>
<source><![CDATA[Treat Endocrinol]]></source>
<year>2003</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-47</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<source><![CDATA[Diabetes Care 2017]]></source>
<year></year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<source><![CDATA[Diabetes Care 2017]]></source>
<year></year>
<volume>40</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parvez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bisher]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Meguid]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and diabetes in the developing world A growing challenge]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>213-5</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of Medical Care in Diabetes-2017]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saacs]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of glucagon-like peptide 1 receptor agonists in management of obesity college of pharmacy -University of Minnesota]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2016</year>
<volume>73</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1493-507</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnett]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus]]></source>
<year>2013</year>
<volume>125</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus]]></article-title>
<source><![CDATA[Ann Rev Med Annu Rev Med]]></source>
<year>2015</year>
<volume>66</volume>
<page-range>255-70</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makimattila]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nikkila]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yki-Jarvinen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1999</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>406-12</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daly]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of insulin and weight gain Optimizing diabetes nutrition therapy]]></article-title>
<source><![CDATA[J Am Dietetic Assoc]]></source>
<year>2007</year>
<volume>107</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1386-93</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
